Perimenopause Hair Loss: Causes, Testing and Regrowth

Perimenopausal hair loss is usually caused by a shift in the ratio of androgens to estrogen acting on genetically susceptible follicles, often compounded by low ferritin or unrecognized thyroid disease. Estrogen holds hair in its growth phase; as estradiol falls, that protection weakens while androgen activity at the follicle becomes relatively more influential. The result is either diffuse shedding, gradual thinning through the crown and part line, or both at once, because the two processes have different mechanisms and frequently coexist. Distinguishing them matters, because they have different tests, different treatments and very different timelines. This article explains the hormonal shift, separates telogen effluvium from female pattern hair loss, sets out the panel worth running, and gives a realistic timeline for regrowth.

In this article

• Falling estradiol changes the androgen-to-estrogen balance at the follicle, not the absolute testosterone level
• Telogen effluvium and female pattern hair loss look similar to patients and different to clinicians
• Ferritin and thyroid function are the two most commonly missed contributors
• A defined lab panel answers most of the diagnostic question
• Protein, iron, zinc and vitamin D matter; biotin almost certainly does not
• Regrowth follows the hair cycle, which means months rather than weeks

The androgen-to-estrogen ratio, not high testosterone

Scalp follicles respond to both estrogen and androgens. Estrogen prolongs anagen, the active growth phase, which is why hair often thickens in pregnancy and sheds afterwards. Androgens, specifically dihydrotestosterone converted from testosterone by 5-alpha reductase within the follicle, progressively shorten anagen and miniaturize susceptible follicles, so each successive hair grows finer, shorter and less pigmented until the follicle stops producing a visible hair.

In perimenopause, estradiol falls faster than ovarian and adrenal androgen output. Sex hormone binding globulin also tends to fall, particularly where insulin resistance is present, and lower SHBG means more free testosterone available to tissue. Total testosterone on a blood test therefore often looks unremarkable while follicle-level androgen exposure has risen. That is the central point most articles miss: pattern hair loss in midlife is usually a ratio and sensitivity problem rather than an androgen excess problem. The Endocrine Society clinical practice guidelines on androgen excess set out when genuine hyperandrogenism should be suspected instead.

Genuine androgen excess does occur and needs excluding. Rapid hair loss with new facial hair, acne, voice deepening, clitoral enlargement or cycle cessation is a different clinical picture and warrants prompt evaluation, including for polycystic ovary syndrome and, rarely, androgen-secreting tumors. Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome (PMOS) by an international consensus published in The Lancet in June 2026.

Telogen effluvium versus female pattern hair loss

These two account for the large majority of midlife hair loss, and they behave differently.

In perimenopause both often run together: an underlying pattern process that was invisible for years becomes obvious after an effluvium from a heavy-bleeding-driven iron drop or an illness. That combination explains why women so often say the loss started suddenly but the thinning never fully recovered.

Three other diagnoses should not be missed. Alopecia areata produces smooth, well-defined round patches. Scarring alopecias, including frontal fibrosing alopecia which has become notably more common in women in this age group, cause loss of follicular openings, sometimes with itch, burning or redness, and require early dermatology referral because the loss is permanent. Traction alopecia from tight styling affects the hairline and temples. Any patchy loss, scalp pain, scaling or shiny skin without visible pores needs examination rather than a supplement.

Interactive tool

Shedding or thinning? Pattern check

Answer four questions from the table above to see whether your hair change looks more like telogen effluvium, female pattern hair loss, or both, and which tests to ask about.

Ferritin and thyroid: the two most commonly missed

Ferritin is the single most useful blood test in a woman with hair shedding. Perimenopausal cycles are frequently heavier and less predictable, and iron stores fall well before hemoglobin does, so a normal complete blood count does not exclude iron-related shedding. Hair follicles are among the most metabolically active tissues in the body and are sensitive to depleted stores. Dermatology practice commonly aims for ferritin comfortably above the lower reference limit in women with hair loss, often quoted as above 30 to 50 ng/mL, although the trial evidence for a specific threshold is limited and this remains a clinical judgment rather than a settled standard. Ferritin also rises with inflammation, so a C-reactive protein alongside it prevents misreading a falsely reassuring value. The NIH Office of Dietary Supplements covers requirements and repletion; iron is not a supplement to take speculatively.

Thyroid disease is the second. Both hypothyroidism and hyperthyroidism cause diffuse shedding, and Hashimoto's thyroiditis is common in women in their 40s and frequently undiagnosed. Thyroid antibodies can be positive years before thyroid-stimulating hormone moves, so a panel including free T4, free T3 and thyroid peroxidase antibodies gives more information than TSH alone. Guidance is published by the American Thyroid Association, and thyroid autoimmunity sits within our autoimmune care. Hair regrowth after thyroid correction lags the biochemical fix by several months, which is a common source of premature disappointment.

The test panel worth running

On that last row, worth being precise. Dried urine metabolite panels such as the DUTCH test report the proportion of androgens traveling down the 5-alpha versus 5-beta pathway, which is the pathway relevant to follicle miniaturization. Precision Analytical has published method-validation work for the assay, but validation of an assay is a different question from clinical validation of a treatment decision, and no outcome trials link these ratios to hair-loss treatment response. Treat the result as context alongside serum values, not as the thing that decides the plan.

Nutrient cofactors that genuinely matter

Hair is roughly 90 percent keratin protein and is a low-priority tissue when supply is constrained, which is why it is an early casualty of restriction.

• Protein and total energy. Sustained low-calorie dieting and low protein intake are among the most reliable causes of effluvium. Aim for adequate intake distributed across the day rather than concentrated in one meal.
• Iron. The strongest nutrient association with hair shedding in women. Correct on the basis of a measured ferritin, with the dose and form decided with your clinician.
• Zinc. Deficiency causes hair loss, and it occurs with malabsorption or restrictive eating. Supplementing without deficiency can induce copper deficiency, so this one should follow a test (NIH ODS).
• Vitamin D. The vitamin D receptor is involved in follicle cycling, and low levels are commonly found in women with hair loss. Whether correcting it improves hair is not established, but correcting a deficiency is worthwhile regardless.
• Biotin. There is no good evidence that biotin helps hair in people who are not deficient, and true deficiency is rare. It does interfere with immunoassays for thyroid hormones, troponin and others, producing misleading results. The NIH Office of Dietary Supplements is clear on both points. If you take it, stop several days before blood tests and tell the laboratory.

A realistic timeline for regrowth

The hair cycle sets the pace, and no intervention shortens it. Anagen lasts two to six years, the brief catagen phase follows, and telogen lasts around three months before the hair is shed and a new one begins. Two consequences follow.

First, cause and effect are separated by about three months. Shedding that starts in September usually reflects something that happened in June: an illness, a crash diet, a heavy-bleeding phase, a stressful period. Women routinely search for a trigger in the wrong month.

Second, correction is equally delayed. After ferritin is repleted or thyroid function normalized, shedding typically slows within two to three months, new short regrowth appears along the part and hairline at three to six months, and density change becomes visible at six to twelve months. For female pattern hair loss, treatment response is conventionally assessed at six to twelve months, and treatment is maintained rather than completed. Photographs in the same light and part every eight weeks are far more reliable than memory, which reliably underestimates progress.

Treatments with evidence, and when to see a dermatologist

Topical minoxidil is the only over-the-counter treatment approved by the FDA for female pattern hair loss and has the strongest evidence base; an initial increase in shedding in the first weeks is expected and is not a reason to stop. Low-level laser therapy devices have moderate evidence and FDA clearance. Anti-androgen prescriptions such as spironolactone are used off-label in women with a suitable profile and require monitoring. Platelet-rich plasma has promising but heterogeneous evidence and no standardized protocol. Hormone therapy is not a treatment for hair loss, though hair sometimes improves when it is used for other menopausal indications; The Menopause Society position statements are the reference for that decision. None of these are self-prescribing decisions.

See a dermatologist promptly for patchy loss, scalp pain, burning, scaling, redness, loss of visible follicular openings, hairline recession at the temples with eyebrow loss, or any rapid loss with new male-pattern hair growth or voice change. Scarring alopecias are treatable only insofar as they are caught early.

Hair change rarely arrives alone. It commonly accompanies the fatigue, sleep disruption and cycle change described in perimenopause fatigue and the wider symptom set in the complete guide to perimenopause, and it is managed as part of perimenopause and menopause care. If you want the underlying drivers worked up rather than the shedding managed in isolation, the functional medicine process page explains how that is structured.

FAQ

Does perimenopause hair loss grow back?

It depends which process is operating. Telogen effluvium is usually fully reversible once the trigger is corrected, with density recovering over six to twelve months. Female pattern hair loss is progressive and does not fully reverse, though treatment can slow it and partially restore density, particularly when started early while follicles are miniaturized rather than lost. Because the two frequently coexist in perimenopause, many women see partial recovery and are then told, incorrectly, that nothing more can be done.

What ferritin level is needed to stop hair shedding?

There is no consensus threshold. Many dermatology practices aim for ferritin above 30 to 50 ng/mL in women with hair loss, which is higher than the lower limit of most laboratory reference ranges, but the supporting trial evidence is limited and the target is a clinical judgment. Ferritin should be interpreted alongside a CRP, because inflammation raises it independently of iron stores. Iron supplementation should follow a measured deficiency and be discussed with your clinician, since excess iron carries its own risks.

Can hormone testing tell me why my hair is thinning?

Partly. Free testosterone with SHBG, DHEA-S, thyroid function and ferritin together answer most of the practical question. Urinary metabolite panels add a view of how androgens are metabolized, including 5-alpha reductase activity, which is mechanistically relevant, but no outcome studies link those ratios to treatment response. Blood tests also cannot show follicle sensitivity, which is genetically determined and is often the deciding factor. Examination of the scalp and the pattern of loss remains essential.

Do hair supplements work?

They work when they correct a genuine deficiency and generally not otherwise. Iron, zinc and protein have clear roles when depleted; biotin has no evidence of benefit in people who are not deficient and interferes with common blood tests, including thyroid assays. Some multi-ingredient supplements show benefit in short manufacturer-funded trials, which is weaker evidence than it appears. Testing first and supplementing to the gap is more effective and cheaper than supplementing on guesswork.

About the author

Medical disclaimer. The information on this page is provided for general education and is not individualized medical advice. At Interlinked Wellness, Anna Evans, MSN, APRN, FNP-C, provides personalized care based on your health history, symptoms, concerns, and goals. An individual consultation allows Anna to evaluate your specific situation and recommend an appropriate approach to care. Reading this page alone does not establish a patient-provider relationship. If you are experiencing a medical emergency, call 911 or your local emergency services.